A multicenter randomized study, (n = 573), that evaluated the role of aspirin in anticoagulated patients undergoing angioplasty. The primary endpoint was the rate of total bleeding, (TIMI), at 12 months follow-up. The administration of a dual therapy, (warfarin + clopidogrel), showed a significant reduction compared with the triple therapy, (19.5% vs. 44.9%, P <0.001). 4 patients were treated without aspirin in order to observe any non-aspirin benefit. Notably, no increased risk for thrombosis or cardiovascular death was observed with the dual therapy. This study has strong repercussions since it demonstrates the safety of this category of complex patients who present hemorrhagic and ischemic high risk. It will probably change the practice of many cardiologists worldwide.
WOEST-slides
Willem Dewilde
2012-08-27
Original title: WOEST: First randomised trial that compares two different regimens with and without aspirin in patients on oral anticoagulant therapy (OAC) undergoing coronary stent placement (PCI)
